The effect of dexmedetomidine in the acute decompensated heart failure

The effect of dexmedetomidine in the acute decompensated heart failure - The effect of dexmedetomidine in the acute decompensated heart failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012323

Enrollment

Registered

2013-11-20

Start date

2013-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

In the acute heart failure, Carperitide administered in addition to the conventional diuretic and cardiotonic medicine Instead of Carperitide, Dexmedetomidine 0.4 ug/kg/h administered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The acute decompensated heart failure which exhibits NYHA3/4

Exclusion criteria

Exclusion criteria: Under systoric blood pressure 80 mmHg

Design outcomes

Primary

Measure	Time frame
Urine output,Catecholamine fraction(dopamine,adrenalin,noradrenalin),Renin activaion,aldosterone,ADH before and after the use od Dexmedetomidine in ADHF Survival rate of one,three,five years	—

Secondary

Measure	Time frame
Creatinine,Heart rate,Blood pressure,Interleukin6,TNF-6,blood serum and urine Na K Cl,blood and urine osmotic pressure	—

Countries

Japan

Contacts

Public Contactfukuda kenji

Higashiosaka City General Hospital cardiovascular medicine

f.kenji.1812@gmail.com06-6781-5101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026